Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism

Movement Disorders : Official Journal of the Movement Disorder Society
N R HughesJ M Brotchie

Abstract

Excessive glutamate transmission in the basal ganglia is a major factor in the neural mechanisms underlying parkinsonian akinesia. Activation of kappa opioid receptors causes a presynaptic reduction in glutamate release. Kappa opioid receptors are concentrated in those regions of the basal ganglia associated with increased glutamate transmission in parkinsonism. In this study, we use the alpha-methyl-p-tyrosine and reserpine-treated rat model of parkinsonism to investigate whether systemic administration of the kappa opioid agonists enadoline (CI-977) and U69,593 can alleviate the symptoms of parkinsonism either alone or in conjunction with dopamine replacement therapy. We report that, when administered alone, both enadoline and U69,593 can increase locomotion in monoamine-depleted rats. No increase in locomotor activity was seen after kappa opioid agonist administration in non-parkinsonian rats. The responses to kappa opioid agonists were blocked by co-administration of either the nonspecific opioid receptor antagonist naloxone or the selective kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI). An important finding is that when enadoline and L-dopa are administered together, their anti-akinetic properties are syne...Continue Reading

References

Oct 26, 1979·Brain Research·J C Reubi, M Cuenod
Jan 1, 1991·Movement Disorders : Official Journal of the Movement Disorder Society·J M BrotchieA R Crossman
Sep 1, 1990·British Journal of Pharmacology·J C HunterJ Hughes
Jun 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R S ZukinA Tempel
Feb 26, 1985·European Journal of Pharmacology·R A LahtiP F Von Voigtlander
Aug 15, 1986·Science·A PfeifferH M Emrich
Sep 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R R Goodman, S H Snyder
Oct 1, 1993·Clinical Neuropharmacology·M GiuffraT N Chase
Jul 25, 1995·European Journal of Pharmacology·M P Hill, J M Brotchie

❮ Previous
Next ❯

Citations

Mar 4, 2000·Peptides·A L VaccarinoA J Kastin
Jan 23, 1999·Current Opinion in Neurobiology·A M LozanoJ O Dostrovsky
Oct 29, 2000·Trends in Neurosciences·T N Chase, J D Oh
Oct 15, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Jul 16, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Gurutz Linazasoro
Aug 25, 2010·Journal of Neuroscience Research·M S NandhuC S Paulose
Feb 6, 2008·Journal of Neural Transmission·G LinazasoroJ A Ruiz Ortega
Nov 27, 2009·Nature·Peter Fratzl, Friedrich G Barth
Jul 12, 2005·CNS Drug Reviews·Juanita Dortch-Carnes, David E Potter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.